Biotech Compass Pathways Q2 operating income beats analyst expectations

COMPASS Pathways

31/07/2025 11:39

Overview

Compass Pathways Q2 operating income beats analyst expectations, driven by warrant liabilities

Net loss for Q2 2025 was $38.4 mln, slightly higher than last year

Cash position of $221.9 million at June 30, 2025; cash runway into 2027

Outlook

COMPASS expects 26-week data from COMP006 trial in H2 2026

Cash position expected to fund operations into 2027

Annual cash outflow from operations expected at $120 mln to $145 mln

Result Drivers

WARRANT LIABILITY IMPACT - Net loss driven by non-cash loss on fair value adjustment related to warrant liabilities

R&D EXPENSES - Increase in expenses due to advancement of late-stage COMP360 Phase 3 clinical trials

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 EPS
-$0.41
Q2 Net Income
-$38.40 mln
Q2 Operating Income
Beat
-$42.93 mln
-$45.50 mln (9 Analysts)
Q2 Operating Expenses
$42.93 mln
Q2 Pretax Profit
-$38.27 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Compass Pathways PLC is $12.00, about 67.2% above its July 30 closing price of $3.94

Press Release: ID:nBw8XlBl1a

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)